Precursor T-lymphoblastic lymphoma/leukaemia recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:36 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Precursor T-lymphoblastic lymphoma/leukaemia recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Ruxolitinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with IL-7R/JAK-STAT Pathway Mutations https://clinicaltrials.eu/trial/study-of-ruxolitinib-and-venetoclax-for-children-with-relapsed-or-refractory-leukemia-or-lymphoma-with-il-7r-jak-stat-pathway-mutations/ Thu, 07 May 2026 05:46:07 +0000 https://clinicaltrials.eu/trial/study-of-ruxolitinib-and-venetoclax-for-children-with-relapsed-or-refractory-leukemia-or-lymphoma-with-il-7r-jak-stat-pathway-mutations/ This clinical trial is focused on studying treatments for children with certain types of blood cancers, specifically Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma, which have either returned after treatment or have not responded to previous treatments. The study involves two medications: Venetoclax, also known by its code name ABT-199, and Ruxolitinib, which is sometimes referred to as INCB018424. These medications are being tested for their effectiveness in treating these cancers, particularly in cases where there are specific genetic changes in the IL-7R/JAK-STAT signaling pathway, which is a part of the body’s cell communication system that can affect cancer growth.

The purpose of the study is to evaluate the safety and effectiveness of these medications in children. Participants in the study will receive either Venetoclax or Ruxolitinib, or a combination of both, in the form of oral tablets or suspensions. The study will be conducted in two phases. The first phase will focus on determining the safest dose of the medications, while the second phase will assess how well the medications work in treating the cancers. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual drugs.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to observe any changes in their condition. The study aims to provide valuable information on the potential benefits of Venetoclax and Ruxolitinib for children with these challenging types of blood cancers. The study is expected to continue until 2031, with recruitment starting in 2024.

]]> Long-term Follow-up Study for Patients with Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma Treated with OC-1 Cells https://clinicaltrials.eu/trial/long-term-follow-up-study-for-patients-with-relapsed-refractory-t-cell-acute-lymphoblastic-leukemia-lymphoma-treated-with-oc-1-cells/ Wed, 29 Apr 2026 15:04:25 +0000 https://clinicaltrials.eu/trial/long-term-follow-up-study-for-patients-with-relapsed-refractory-t-cell-acute-lymphoblastic-leukemia-lymphoma-treated-with-oc-1-cells/ This clinical trial focuses on patients with T-cell acute lymphoblastic leukemia and T-cell acute lymphoblastic lymphoma, which are types of blood cancers. The study involves a treatment called OC-1, which uses a special type of cell therapy. In this treatment, a patient’s own T-cells, a type of white blood cell, are modified outside the body using a lentiviral vector. This vector helps the T-cells develop a chimeric antigen receptor (CAR) that specifically targets a protein called CD1a on cancer cells. The modified T-cells, known as hCD1a-CAR T cells, are then infused back into the patient’s bloodstream.

The purpose of this study is to monitor patients who have already received the OC-1 cell therapy. The study will follow these patients for up to 15 years to check for any delayed side effects or adverse events. This long-term follow-up is important to ensure the safety of the treatment and to understand any potential risks that may arise over time. The study will look at various outcomes, such as the number of serious side effects, the development of new health issues, and the overall survival of patients after receiving the therapy.

During the study, researchers will also assess how long the OC-1 cells remain in the body and how they affect the patient’s health. This includes checking for the presence of the modified T-cells in the blood and evaluating their impact on the patient’s immune system. The study aims to provide valuable information about the long-term effects of this innovative treatment for patients with these challenging types of cancer.

]]> Study on the Safety and Effectiveness of OC-1 Therapy for Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoma https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-oc-1-therapy-for-patients-with-relapsed-or-refractory-t-cell-acute-lymphoblastic-leukemia-or-lymphoma/ Wed, 29 Apr 2026 15:01:48 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-oc-1-therapy-for-patients-with-relapsed-or-refractory-t-cell-acute-lymphoblastic-leukemia-or-lymphoma/ This clinical trial is focused on studying the safety and effectiveness of a new treatment called hCD1a-CAR T (also known as OC-1) for patients with a type of blood cancer known as T-cell Acute Lymphoblastic Leukemia or T-cell Acute Lymphoblastic Lymphoma. These are aggressive forms of cancer that affect the white blood cells, and the study is specifically for patients whose cancer has returned or has not responded to previous treatments. The treatment involves using the patient’s own immune cells, which are modified outside the body to better recognize and attack cancer cells when reintroduced into the bloodstream.

The purpose of the study is to assess the safety of this new treatment in patients with relapsed or refractory CD1a-positive T-cell cancers. Participants in the study will receive the hCD1a-CAR T therapy through an intravenous infusion, which means the treatment is delivered directly into the bloodstream. The study will monitor patients for any side effects and evaluate how well the treatment works in controlling the cancer. Some patients may receive a placebo as part of the study to compare the effects of the new treatment.

Throughout the study, patients will have regular check-ups to assess their health and the response of their cancer to the treatment. The study aims to gather information on the remission rates, which is the period during which the cancer is under control, and overall survival, which is the length of time patients live after receiving the treatment. The study will also look at how long the modified immune cells remain active in the body. This research is important for developing new therapies for patients with these challenging types of cancer.

]]> Study on Trametinib, Dexamethasone, Cyclophosphamide, and Cytarabine for Children with Relapsed or Refractory Blood Cancer https://clinicaltrials.eu/trial/study-on-trametinib-dexamethasone-cyclophosphamide-and-cytarabine-for-children-with-relapsed-or-refractory-blood-cancer/ Wed, 29 Apr 2026 14:26:45 +0000 https://clinicaltrials.eu/trial/study-on-trametinib-dexamethasone-cyclophosphamide-and-cytarabine-for-children-with-relapsed-or-refractory-blood-cancer/ This clinical trial is focused on studying certain types of blood cancers in children, specifically Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma, which can be either in relapse or resistant to treatment. The study aims to explore the effects of a combination of medications, including Trametinib, Dexamethasone, Cyclophosphamide, and Cytarabine. These medications are being tested to see how safe they are and how well they work in treating these cancers.

The trial is divided into two phases. In the first phase, the focus is on determining the safest dose of the medications that can be given to patients. The second phase aims to evaluate how effective these medications are in treating patients with specific genetic changes in their cancer cells. The study involves taking these medications in different forms, such as tablets or injections, over a period of time. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects.

Throughout the study, the health and progress of the participants will be closely monitored. This includes regular check-ups and tests to assess how the body is responding to the treatment. The goal is to gather information that could lead to better treatment options for children with these challenging types of blood cancer. The study is expected to continue until 2030, with the hope of providing valuable insights into the treatment of these diseases.

]]> Study of Dasatinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with MAPK/SRC Pathway Mutation https://clinicaltrials.eu/trial/study-of-dasatinib-and-venetoclax-for-children-with-relapsed-or-refractory-leukemia-or-lymphoma-with-mapk-src-pathway-mutation/ Wed, 29 Apr 2026 14:22:35 +0000 https://clinicaltrials.eu/trial/study-of-dasatinib-and-venetoclax-for-children-with-relapsed-or-refractory-leukemia-or-lymphoma-with-mapk-src-pathway-mutation/ This clinical trial is focused on studying certain types of blood cancers in children, specifically Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. These conditions are being examined when they have returned after treatment or have not responded to treatment. The study involves two medications: Venetoclax, also known by its code name ABT-199, and Dasatinib. Venetoclax is available as an oral suspension and film-coated tablets, while Dasatinib is available as film-coated tablets and powder for oral suspension. Both medications are designed to target cancer cells and are classified as anti-neoplastic agents, which means they work to stop the growth of cancer cells.

The purpose of this study is to explore the safety and effectiveness of these medications in children with specific genetic changes in their cancer cells. These changes are related to the MAPK/SRC signaling pathway, which is a series of interactions between proteins in a cell that can lead to cancer growth. The study is divided into two phases. The first phase aims to determine the safest dose of the medications, while the second phase evaluates how well the medications work in treating the cancer. Participants will receive either Venetoclax or Dasatinib, or a combination of both, and their health will be monitored closely throughout the study.

During the trial, participants will take the medications orally, either as a liquid or a tablet, depending on the formulation. The study will track various outcomes, such as the overall response to the treatment and the time it takes for the cancer to return, if it does. The trial will also assess the quality of life of participants using a specific questionnaire designed for children with cancer. The study is expected to continue until 2031, with recruitment starting in 2024.

]]>